Dyadic International, Inc. (DYAI)
NASDAQ: DYAI · Real-Time Price · USD
1.380
+0.030 (2.22%)
Apr 1, 2025, 4:00 PM EDT - Market closed
Dyadic International Revenue
In the year 2024, Dyadic International had annual revenue of $3.50M with 20.58% growth. Dyadic International had revenue of $817.38K in the quarter ending December 31, 2024, with 19.06% growth.
Revenue (ttm)
$3.50M
Revenue Growth
+20.58%
P/S Ratio
11.32
Revenue / Employee
$499,341
Employees
7
Market Cap
41.53M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3.50M | 596.58K | 20.58% |
Dec 31, 2023 | 2.90M | -31.50K | -1.07% |
Dec 31, 2022 | 2.93M | 526.47K | 21.90% |
Dec 31, 2021 | 2.40M | 801.91K | 50.06% |
Dec 31, 2020 | 1.60M | -79.16K | -4.71% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
DYAI News
- 5 days ago - Dyadic International, Inc. (DYAI) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Dyadic Reports 2024 Year-End Financial Results and Business Updates - GlobeNewsWire
- 20 days ago - Dyadic to Report 2024 Full Year Financial Results and Host Conference call on Wednesday, March 26, 2025 - GlobeNewsWire
- 26 days ago - Dyadic to Attend Multiple Industry Events in March - GlobeNewsWire
- 3 months ago - Dyadic Provides Business Update; Dyadic to Attend the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 4 months ago - Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology - GlobeNewsWire
- 4 months ago - Dyadic International, Inc. (DYAI) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 months ago - Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 - GlobeNewsWire